ABT vs GEHC
Abbott Laboratories and GE HealthCare, both Healthcare
Abbott Laboratories is the larger company at $154B against $28B. On trailing earnings GEHC is the cheaper of the two at a P/E of 15.7 against 27.8, a gap that is only a bargain if the two are growing at similar rates. Over the past year GEHC returned -11% against -25% for ABT.
| Figure | ABT | GEHC |
|---|---|---|
| Last close | $99.59 | $65.73 |
| Market cap | $154B | $28B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.8 | 15.7 |
| Dividend yield | 2.4% | 0.2% |
| 1-year return | -25% | -11% |
| 5-year return | -14% | n/a |
| RyuScoresector-relative, 1–10 | 60/100 | 60/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Abbott Laboratories
Revenue of $11B in Q1 2026, net income $1.1B. Its largest reported line is Nutritional Products, 41% of the disclosed total.
GE HealthCare
Revenue of $5.1B in Q1 2026, net income $389M. Its largest reported line is AIS, 64% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.